Tag
This article examines how the timing of bilateral salpingo-oophorectomy (BSO) affects the lifetime ovarian cancer risk in women carrying BRCA1 or BRCA2 mutations, emphasizing the benefits of preventive surgery and its residual risk reductio
County-level social vulnerability significantly limits ovarian cancer clinical trial availability, underscoring structural inequities and the need for targeted strategies to improve trial access in vulnerable communities.
A novel AI-driven risk prediction model for ovarian cancer demonstrates high accuracy and potential to improve early detection in screening settings.
A quality improvement initiative integrating oral anticoagulants reduced venous thromboembolism incidence in ovarian cancer patients undergoing first-line chemotherapy without increasing bleeding risks.
This article analyzes 40-year trends in incidence, mortality, and survival of endometrial, ovarian, and cervical cancers among Nordic women aged 0-49, highlighting evolving epidemiology and implications for age-specific prevention.
The OPAL phase 2 trial compared neoadjuvant niraparib to standard platinum-taxane chemotherapy in newly diagnosed HR-deficient advanced ovarian cancer, showing inferior response rates with niraparib and a safety profile consistent with PARP
This study assesses the predictive accuracy of the MSKCC CT-based model for residual disease after neoadjuvant chemotherapy in advanced ovarian cancer, showing limited discrimination that improves with optimized clinical parameters. CT find
The PRO-PLATINUM trial evaluates a novel 5-strain probiotic’s effect on gut and vaginal microbiome composition and clinical outcomes in ovarian cancer patients undergoing platinum chemotherapy, assessing safety, feasibility, and trans
This international study reveals that many patients with platinum-sensitive recurrent ovarian cancer achieve durable, progression-free survival exceeding 5 years on PARP inhibitors, even after treatment discontinuation, with a low risk of s
A large real-world registry study shows that ovarian cancer patients aged 70 and older still carry clinically actionable germline variants, often without a reported family history, supporting broader age-inclusive genetic testing.
Study shows post-diagnosis estrogen therapy improves survival in high-grade serous and clear cell ovarian cancers but may worsen outcomes in endometrioid subtypes, offering guidance for managing menopausal symptoms in younger survivors.
A US cohort study of 543 ovarian cancer patients revealed 37% experienced decreased platelets during niraparib maintenance. Onset typically occurred within 1 month but resolved rapidly with dose adjustments, resulting in low discontinuation
A large-scale cohort study of over 15,000 patients reveals that isolated tumor cells (ITCs) in regional lymph nodes do not significantly impact short-term overall survival in epithelial ovarian cancer, despite higher prevalence in low-grade
A phase 3 randomized clinical trial demonstrates that 6 weeks of mobile app-guided self-acupressure significantly and sustainably reduces fatigue in ovarian cancer survivors compared to usual care, providing a safe, low-cost digital health
The European Society of Gynaecological Oncology (ESGO) has released new consensus statements advocating for opportunistic salpingectomy—removing fallopian tubes during unrelated surgeries—to significantly reduce ovarian cancer risk without
A large-scale population study confirms that removing fallopian tubes during unrelated pelvic surgeries reduces serous ovarian cancer risk by 78%, providing robust evidence for its use as a primary prevention strategy against high-grade ser
A massive cohort study of 2.2 million women reveals that ovarian cancer risk factors vary significantly by menopausal status and birth year. While early menarche and low parity remain universal risks, the protective benefits of breastfeedin
Highlights Background: The Unique Challenge of Low-Grade Serous Ovarian Cancer Low-grade serous ovarian carcinoma (LGSOC)...
Two randomized phase III trials tested adding atezolizumab to bevacizumab plus chemotherapy in recurrent ovarian cancer. Neither AGO‑OVAR 2.29/ENGOT‑ov34 (non‑platinum, platinum‑resistant) nor ATALANTE/ENGOT‑ov29 (platinum‑sensitive) met th
This article discusses the application of the estimand framework to evaluate clinical effectiveness of risk-reducing early salpingectomy with delayed oophorectomy in women with high ovarian cancer risk due to BRCA mutations, based on data f
